Payment overview · 2025
General Payments
$29,602.86
253 reported records · 12 companies
Healthcare provider profile · identity verified
Rajesh Malik, M.D.
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · NAPLES, FL · NPI 1578753257
Verified facts
What the public records show
CMS Open Payments records show Rajesh Malik, M.D. received $29,602.86 in general payments during 2025 across 253 reported records.
Medtronic, Inc. accounted for 44.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$13,026.49 | 44.0% | 111 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $6,247.00 | 21.1% | 66 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $5,541.43 | 18.7% | 21 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $1,996.82 | 6.8% | 10 | 2025 |
| Cagent Vascular INC | Unresolved — no canonical attribution shown | $1,132.59 | 3.8% | 29 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $811.66 | 2.7% | 8 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $260.76 | 0.9% | 2 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $194.32 | 0.7% | 1 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $165.32 | 0.6% | 1 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $155.96 | 0.5% | 2 | 2025 |
| ARGON MEDICAL DEVICES, INC. | Unresolved — no canonical attribution shown | $42.33 | 0.1% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $28.18 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $13,718.33 | 232 |
| Travel and Lodging | $8,034.53 | 17 |
| Compensation for serving as faculty or as a speaker for a medical education program | $4,100.00 | 3 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,750.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $5,445.23 | 35 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $5,309.50 | 22 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $5,053.58 | 14 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc., Stryker Corporation | $2,893.48 | 13 | 2025 |
Source payment records
|
|||||
| LIMFLOW SYSTEM Normalized: limflow system |
Device | Stryker Corporation | $2,143.77 | 26 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis Normalized: gore excluder thoracoabdominal branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $1,996.82 | 10 | 2025 |
Source payment records
|
|||||
| Serrantor Normalized: serrantor |
Device | Cagent Vascular INC | $1,132.59 | 29 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $896.53 | 14 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc., Stryker Corporation | $825.14 | 12 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $811.66 | 8 | 2025 |
Source payment records
|
|||||
| VALIANT CAPTIVIA Normalized: valiant captivia |
Device | Medtronic, Inc. | $491.42 | 12 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $338.51 | 11 | 2025 |
Source payment records
|
|||||
| CONCERTOTM Normalized: concertotm |
Device | Medtronic, Inc. | $325.92 | 8 | 2025 |
Source payment records
|
|||||
| IN.PACT AV Normalized: in pact av |
Device | Medtronic, Inc. | $278.31 | 8 | 2025 |
Source payment records
|
|||||
| SILVERHAWK Normalized: silverhawk |
Device | Medtronic, Inc. | $247.40 | 3 | 2025 |
Source payment records
|
|||||
| TURBOHAWK Normalized: turbohawk |
Device | Medtronic, Inc. | $228.51 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $194.32 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $194.32 | 1 | 2025 |
Source payment records
|
|||||
| MVP Normalized: mvp |
Device | Medtronic, Inc. | $186.47 | 5 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $145.37 | 1 | 2025 |
Source payment records
|
|||||
| ENSITE Normalized: ensite |
Device | Abbott Laboratories | $142.05 | 1 | 2025 |
Source payment records
|
|||||
| CHOCOLATE PTA BALLOON CATHETER Normalized: chocolate pta balloon catheter |
Device | Medtronic, Inc. | $140.98 | 3 | 2025 |
Source payment records
|
|||||
| ABSOLUTE PRO Normalized: absolute pro |
Device | Abbott Laboratories | $140.74 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $130.67 | 4 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $117.29 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $115.39 | 1 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK PERIPHERAL Normalized: diamondback peripheral |
Device | Abbott Laboratories | $110.61 | 3 | 2025 |
Source payment records
|
|||||
| PROTEGE RX Normalized: protege rx |
Device | Medtronic, Inc. | $71.98 | 2 | 2025 |
Source payment records
|
|||||
| EMBOSHIELD NAV6 Normalized: emboshield nav6 |
Device | Abbott Laboratories | $68.36 | 1 | 2025 |
Source payment records
|
|||||
| CLOT MANAGEMENT Normalized: clot management |
Device | ARGON MEDICAL DEVICES, INC. | $42.33 | 1 | 2025 |
Source payment records
|
|||||
| CRAGG-MCNAMARATM Normalized: cragg mcnamaratm |
Device | Medtronic, Inc. | $37.22 | 1 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $31.48 | 1 | 2025 |
Source payment records
|
|||||
| ENTEER Normalized: enteer |
Device | Medtronic, Inc. | $30.16 | 2 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $28.18 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $28.18 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $26.09 | 1 | 2025 |
Source payment records
|
|||||
| SPIDERFX Normalized: spiderfx |
Device | Medtronic, Inc. | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| NANOCROSS ELITE Normalized: nanocross elite |
Device | Medtronic, Inc. | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| MO.MA ULTRA Normalized: mo ma ultra |
Device | Medtronic, Inc. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| HELI-FX ENDOANCHOR SYSTEM Normalized: heli fx endoanchor system |
Device | Medtronic, Inc. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 23 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $29,602.86 · 253 records | Medtronic, Inc. | ABRE, ABSOLUTE PRO, ARTIX MT, CHOCOLATE PTA BALLOON CATHETER, CLOT MANAGEMENT, CLOTTRIEVER BOLD CATHETER, CONCERTOTM, CRAGG-MCNAMARATM, CT THROMBECTOMY SYSTEM KIT, DIAMONDBACK PERIPHERAL, EMBOSHIELD NAV6, ENDURANT IIS, ENROUTE Transcarotid Neuroprotection System, ENSITE, ENTEER, ESPRIT, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, Flexitouch Plus, GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, HAWKONE, HELI-FX ENDOANCHOR SYSTEM, IN.PACT ADMIRAL, IN.PACT AV, Kerecis GraftGuide, Kerecis SurgiClose, LIMFLOW SYSTEM, MO.MA ULTRA, MVP, NANOCROSS ELITE, Nimbl, PERCLOSE PROSTYLE, PROTEGE RX, SILVERHAWK, SPIDERFX, Serrantor, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TURBOHAWK, VALIANT CAPTIVIA, WATCHMAN FLX | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error